Navigation Links
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
Date:7/31/2008

e its goal of having no more than 5% of

patients lost to follow-up at the time of the week 72

assessment.

ITMN-191:

-- On April 2, InterMune reported top-line results in the four dose

cohorts of treatment-naive patients chronically infected with

hepatitis C virus (HCV) genotype 1 in its Phase 1b multiple-

ascending-dose (MAD) monotherapy trial of ITMN-191:

-- Day 14 median viral kinetic results competitive with those

published for other direct antiviral compounds when used in

monotherapy for 14 days. Specifically, InterMune reported a

median 3.8 log reduction (equal to 99.98% reduction) in HCV RNA

from baseline at Day 14;

-- Significant and rapid viral kinetic activity when dosed every

12 hours; and

-- Excellent safety and tolerability in all dosage regimens.

-- InterMune reported successful completion of 13-week toxicology

studies in rats and monkeys at exposures higher than those expected

to be evaluated in clinical studies. These preclinical studies were

required before initiating the Phase 2 program of ITMN-191 which

will involve durations of therapy longer than those studied in Phase

1.

-- Announced on May 29 the initiation of a 14-day study of ITMN-191 in

combination with Pegasys(R) (pegylated interferon alpha-2a) and

Copegus(R) (ribavirin). The study is proceeding as planned.

-- Submitted several abstracts for possible presentation at the 59th

Annual Meeting of the American Association for the Study of Liver

Diseases (AASLD) to be held October 31 - November 4, 2008 in San

Francisco, including but not limited to data on ITMN-191.

Financial:

-- On June 24, InterMune exchanged $85 million
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... North Carolina (PRWEB) October 27, 2014 ... invited earlier this month to sit down with Bryan Hamilton, ... from RPG Solutions to discuss talent in the Research Triangle ... topics that were highlighted at the roundtable include ... the Triangle, the significance of work/life balance and the unique ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 ... (OTCQB: GNBT) today announced two presentations demonstrating that ... its novel proprietary cancer immunotherapeutic AE37 vaccine correlated ... patients. The AE37 cancer vaccine is being developed ... ( www.antigenexpress.com ). The presentations are being made ...
(Date:10/27/2014)... MA (PRWEB) October 27, 2014 ... profit. SoundConnect , an industry leading unified ... its partners and agents to deliver cloud-based audio ... accelerate growth opportunities. , With SoundConnect’s Q4 ... every twenty-five video and/or web conferencing licenses sold, ...
(Date:10/27/2014)... Mass. , Oct. 27, 2014 ... "Company"), a worldwide leader in the development and ... the life sciences research market, today announced that ... presented a novel, accurate, highly reproducible, and robust ... – routine high-throughput protein analysis on small needle ...
Breaking Biology Technology:Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4SoundConnect Unveils Q4 Partner Incentives 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5
... At the 44th Annual Meeting of,the American Society ... the potential utility of Zevalin(R) (Ibritumomab,Tiuxetan) radioimmunotherapy as ... chemotherapy in the treatment of non-Hodgkin,s,lymphoma (NHL). Cell ... markets,Zevalin in the United States., "These two ...
... CITY, China, May 30 /Xinhua-PRNewswire-FirstCall/ -- China,Pharma Holdings, ... which develops, manufactures, and markets generic and branded,bio-pharmaceutical ... 30, 2008,it closed its recently announced financing, issuing ... price of $2.00 per share and three-year warrants,to ...
... PRINCETON, N.J., May 30 Pharmacopeia (Nasdaq:,PCOP), an ... small,molecule therapeutics, announced today that it is implementing ... its resources on the company,s clinical,and later-stage discovery ... approximately 15 percent through attrition and,termination of positions ...
Cached Biology Technology:Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma 2Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma 3Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma 4China Pharma Holdings, Inc. Closes $10 Million Financing 2China Pharma Holdings, Inc. Closes $10 Million Financing 3Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs 2Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs 3Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs 4
(Date:10/29/2014)... in New York City on September 19, 2014, leading ... Society Professor of Genome Sciences and Medicine at the ... of Philosophy of Tel Aviv University, was awarded the ... In addition to her honorary degree from TAU, Prof. ... School of Medicine, and for the past 18 years ...
(Date:10/29/2014)... potential of the Barcode of Life Data Systems ... Biodiversity Data Journal (BDJ) used specimen ... these into a human-readable text developed in manuscript within ... used to study the species distributions of ten Nearctic ... BOLD is originally designed to support the generation and ...
(Date:10/29/2014)... Genomics of the Kidney consortium ( CAGEKID ) ... exposure to aristolochic acid, an ingredient in some ... Communications , have important implications for public health. ... every year, and in Central Europe incidence rates ... International Cancer Genome Consortium (ICGC), has been studying ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Kidney cancer in Central Europe 2
... amphibians developed the ability to feed on land before ... University report this week in the Proceedings of the ... on analysis of the skulls of the first amphibians, ... ancestors. The shapes of the junctions between adjacent skull ...
... Atlantic Ocean doesn't receive the mother lode of fixed nitrogen, ... for fathom, the Pacific and Indian oceans experience twice the ... the Jan. 11 issue of Nature. , The title of ... for N2 Fixation in all the Wrong Places." ...
... Why have large outbreaks of Ebola virus killed tens ... decade? Observations published in the May issue of The ... be amplified by Ebola transmission between ape social groups. ... control the devastating impact of Ebola on wild apes. ...
Cached Biology News:Ancient amphibians evolved a bite before migrating to dry land 2New findings blow a decade of assumptions out of the water 2New findings blow a decade of assumptions out of the water 3Ebola outbreaks killing thousands of gorillas and chimpanzees 2
Potassium Channel kv3.2...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
MAb to Vasopressin Preservative: NaN3...
Biology Products: